$2.85
+0.02 (+0.71%)
Open$2.82
Previous Close$2.83
Day High$2.85
Day Low$2.81
52W High$3.24
52W Low$1.29
Volume—
Avg Volume418.3K
Market Cap268.06M
P/E Ratio7.58
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,530.2% upside
Current
$2.85
$2.85
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.95M | 14.58M | 13.34M |
| Net Income | 35.43M | 2.88M | 3.22M |
| Profit Margin | 48.6% | 19.8% | 24.2% |
| EBITDA | 32.36M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | +113.3% | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |